Quality of Life Clinical Trial
Official title:
Short- and Medium-term Safety/Effectiveness Analysis of Low Energy Holmium Laser Enucleation of the Prostate (HoLEP)
The purpose of this study is to prove that low-energy (30W) Holmium laser prostatectomy (Holeb) is not inferior to high-energy (100W) Holmium laser prostatectomy (safety and effectiveness)
1. Overview of the study Research design: prospective, single-arm blind randomized control
study, non-inferiority study Study Period: 12 months since IRB approval date Subject:
Patients with benign prostatic hyperplasia Number of study subjects: 90 Vulnerable
Subjects: None
2. Background and purpose of the study
1) Research background
1. Overview and main symptoms of prostatic hyperplasia (BPH)
-The prostate is a male reproductive organ located in the lower bladder. Benign
prostatic hyperplasia (BPH) causes lower urinary tract symptoms (LUTS) due to bladder
outlet obstruction.
- The prevalence of prostatic hyperplasia is known to reach 37% in the 50s, 49% in
the 60s, and 70% in the 70s; a disease with a very high incidence in long-aged men.
- BPH is a disease directly related to the quality of life that interferes with the
patient's social life, sexual life, and daily life. If it persists for a long time,
it may cause bladder stones, hematuria, and even renal dysfunction, so timely
treatment is absolutely necessary.
2. Surgical Treatment of BPH
-Surgical treatment is recommended for an enlarged prostate that is not treated with
drugs, and transurethral surgery using an endoscope is recommended for standard surgery
for an enlarged prostate.
- Transurethral surgery for BPH varies from traditional transurethral resection of
the prostate (TURP) to holmium laser enucleation of the prostate (HoLEP).
- HoLEP has a sharp increase in the number of surgeries worldwide due to its low
recurrence rate, high efficiency, and high patient satisfaction;
- Since its first introduction in 2008 in Korea, the number and rate of surgeries
have been steadily increasing. The total number of surgery for BPH is equivalent to
about 10,000 cases per year. TUR-P and KTP laser surgery are on a decreasing trend,
while HoLEP is on an increasing trend.
3. The importance of HoLEP
-HoLEP is a surgery to completely remove prostate tumors using a Holmium-YAG Laser of
2100nm wavelength.
-The tissue penetration depth of the Holmium laser is less than 0.44mm, enabling sharp
incisions, and has the advantage of less bleeding than traditional transurethral
prostatectomy.
-The surgery principle of HoLEP is fundamentally different from TUR-P and KTP laser
prostate vaporization. TUR-P and KTP laser prostatectomy aim to remove part of the
prostate tumor, whereas HoLEP performs complete removal of the prostate tumor according
to the anatomical structure.
-HoLEP consists of two steps, and the first step consists of an enucleation step in
which the prostate tumor is completely removed and placed in the bladder, and a
morcellation step in which the enucleated adenoma tissue is morcellated and removed.
- HoLEP is relatively safe compared to other transurethral surgery and can completely
remove prostate adenoma, so it has a low recurrence rate and the patient's
satisfaction with surgery is over 90%, making it the next-generation standard
treatment for BPH.
4. Low energy HoLEP related research and clinical status -HoLEP is mainly applied to
treatment with 80-100 Watt high energy equipment. High-energy HoLEP has the advantage of
removing prostate tumors in a short time, but there are problems of frequent laser fiber
damage, device shutdown problems, and possible bladder damage due to scattered lasers.
- In 2008, Rassweiller et al. proposed the possibility of clinical application of low
energy HoLEP by applying a 40 Watt Holmium laser. Since then, prospective studies
have been published sporadically. In 2018, a prospective randomized study that
compared and analyzed the prostate removal efficiency of 50 Watt laser and 100 Watt
laser in a total of 121 patients was the latest and largest study and confirmed
that low-energy prostatectomy is not inferior to the high-energy procedure. And
proved its clinical safety.
- In theory, low-energy HoLEP reduces dysuria immediately after surgery and storage
symptoms after surgery. It is estimated to be advantageous in preserving erectile
function.
- The research team is the first in the world to compare the safety and usefulness of
30 Watt HoLEP with 100 Watt HoLEP through prospective, non-inferiority studies.
2) Research goal The final purpose of the study: To prove that the low-energy
(30Watt) HoLEP is not inferior to the high-energy (100Watt) HoLEP in short-term and
mid-term surgical results (safety and effectiveness).
Detailed research objectives:
1. Compare short-term (2 weeks-1 months) surgical outcomes/surgical complications of low
energy HoLEP with high energy HoLEP.
2. Compare the mid-term (3, 6 months) surgical outcomes/surgical complications of
low-energy HoLEP with high-energy HoLEP.
3) Selection criteria, exclusion criteria, the target number of subjects and basis for
calculation
- Selection criteria Men over 50 Patients receiving HoLEP due to an enlarged prostate
Patients who fully understood and agreed to the study
- Exclusion criteria Patients with neuropathy that may adversely affect the urination
function (Parkinson's disease, dementia, etc.) Patients with acute urinary retention
within the last month Patients with symptomatic urinary tract infection In case there
are other factors that can significantly affect treatment results at the discretion of
the researcher
(2) Number of research subjects About 90 patients
- The basis for calculating the number of subjects This study aims to prospectively enroll
and randomize prostatectomy patients, and then compare the results of the treatment at 6
months after the maximum operation to confirm non-inferiority.
The current standard is a method using a high-energy holmium laser, and the treatment results
for 6 months after surgery have been published through many studies. The research team wants
to confirm the surgical outcome as a decrease in the International Prostate Symptom Score
(IPSS). After 6 months of predicted high-energy HoLEP, IPSS in other literature (5.1 ± 5.0),
6 months after the expected of low-energy HoLEP. IPSS is estimated from the most recently
published academic paper (5.0 ± 5.0).
Alpha (0.15) and Beta (0.8) were calculated, and the non-inferior margin was set to 3. The
estimated number of subjects is calculated by considering the 20% drop-out rate. Statistics
for calculating the number of subjects are calculated using PASS 2019.
Considering drop-out 20%, it is necessary to recruit 25-114 patients (total 50-114) per group
to conduct the study.
This organization is an organization that implements about 20-30 HoLEP cases per month, and a
follow-up period of up to 6 months is required to announce short-term and mid-term results.
Therefore, the actual patient enroll period is estimated to be up to 6 months. It is expected
that 120-180 patients can undergo surgery during the recruitment period of up to 6 months,
and assuming that only 60% of patients will participate in the study based on the median of
about 150, a total of 90 patients, about 45 for each group. It is judged realistic to conduct
a study with 3 patients.
4. Research method
1. Specific research method Since the researchers have already published dozens of studies
related to HoLEP surgery, we are securing a systematic preoperative
examination/postoperative follow-up process. The preoperative examination/postoperative
follow-up protocol of high energy HoLEP surgery, which was previously performed, will be
used as it is, but the study will be conducted by adding only the preoperative
randomization process.
-Pre-screening: After making operation in the outpatient clinic, before hospitalization,
it is checked whether it is subject to enroll according to the patient record.
-Random allocation: Using R package (RandomizeR), low energy HoLEP, and high energy
HoLEP is randomly assigned.
-Pre-Op work-up & Operation: This item is irrelevant to Randomization and is a situation
where you do not know who will undergo surgery, so it is considered a normal treatment
process and proceeds according to the existing process.
- Monitoring: It is planned to perform research ethics, safety, and monitoring work
independently from the researcher by requesting the Medical Device Innovation
Center.
- Clinical trial insurance: In case of adverse side effects to patients, the company
plans to subscribe to clinical trial liability insurance through the Medical Device
Innovation Center to notify the patient of the procedures and details of the
clinical trial damage relief.
- Compensation: There is no monetary incentive for research participants, and the
research team will pay 30,000 won of transportation and inspection costs (160,000
won) per visit during the participation period of visit #1-#3.
2. Test drug administration/dosage, administration/use method, combination therapy, reasons
for selection when using a reference drug None
3. Observation items, clinical test items and observation test methods Primary endpoint:
3-6 month questionnaire (International Prostate Symptom Score, IPSS) total score
Secondary endpoint:
1) Surgery day: surgery time, total energy, resected prostate volume, immediate complication
1) 2 weeks after surgery: questionnaire (IPSS-subscore, IPSS-QoL, OABSS total score), Qmax,
2) post voided residual urine volume, Clavian-Dindo complication classification 3) 3, 6
months after surgery: questionnaire (IPSS-total, IPSS subscore, IPSS-QoL, OABSS total score),
Qmax, post voided residual urine volume, Clavian-Dindo complication classification, urine
test (urinalysis, urine microscopy), serum PSA level
4) Effect evaluation criteria, evaluation method Efficacy
1. Statistical analysis of low-power HoLEP is not inferior in short-term (2wk/1month) and
mid-term (3-6 months) IPSS.
2. Uroflowmetry (UFM) and non-inferiority of post voided residual (PVR) were verified in
urinalysis.
3. 3 months/6 months U/A, micro, 6 months PSA
4. Non-inferiority was verified in terms of improving the patient's QoL.
5. To verify the non-inferiority of the storage symptom subscore after the patient's
surgery.
Safety:
1. The safety of HoLEP has been revealed to some extent through overseas research results,
so animal testing is not required. For the safety, all safety issues that occurred using
the Clavian-Dindo grade, which are commonly used clinically in human studies, were
recorded and compared and analyzed.
2. If adverse events that occurred immediately after surgery and during up to 3 visits were
recorded and there was a statistically significant difference in complications of Grade
III-IV, it was judged that there was a safety problem.
4) The difference between existing treatment and research Existing studies comparing low
energy HoLEP surgery and high energy HoLEP are mostly retrospective studies, and two
prospective studies have been performed.
One of the two prospective studies involved 54 patients and had no active control group.
The most recent study was RCT with 121 subjects, but it was a study comparing 50W laser and
100W laser.
This study is the first in the world to compare 30W laser and 100W laser, and it is a
prospective, RCT that recruits 90 patients, and it is judged that the results of the study
can provide important medical evidence for the safety and effectiveness of low-energy HoLEP
surgery.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Completed |
NCT06238557 -
Prospective Evaluation of Psychological Consequences and Impact on Long-term Quality of Life
|
||
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT05472935 -
Asynchronous Mindfulness Based Stress Reduction to Reduce Burnout in Licensed Clinical Social Workers
|
N/A | |
Recruiting |
NCT04444544 -
Quality of Life and High-Risk Abdominal Cancer Surgery
|
||
Completed |
NCT04281953 -
Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
|
||
Recruiting |
NCT05546931 -
Mobile Health Program for Rural Hypertension
|
N/A | |
Active, not recruiting |
NCT04746664 -
Effects of Nutrition Counselling on Old Age People's Nutritional Status and Quality of Life in Bahir Dar City, North West Ethiopia
|
N/A | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Recruiting |
NCT04142827 -
The Effect of Long Term Therapy With High Flow Humidification Compared to Usual Care in Patients With Bronchiectasis (BX)
|
N/A | |
Active, not recruiting |
NCT05903638 -
A Pilot RCT: the Impact of a Virtual MBSR Course on Women With Primary Infertility
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Completed |
NCT06216015 -
Exercise Training and Kidney Transplantation
|
N/A | |
Completed |
NCT03813420 -
Sleep Quality of Physiotherapy Students Quality of Life and Physical Activity Level
|
N/A | |
Recruiting |
NCT05550545 -
Infant RSV Infections and Health-related Quality of Life of Families
|
||
Completed |
NCT05346588 -
THRIVE Feasibility Trial
|
Phase 3 | |
Recruiting |
NCT05233020 -
Robotic Versus Hybrid Assisted Ventral Hernia Repair
|
N/A | |
Terminated |
NCT03304184 -
The Role of Biodentine in Class V Dental Lesions on Oral Health Related Quality of Life
|
Phase 3 | |
Completed |
NCT05063305 -
Probiotics, Immunity, Stress, and QofL
|
N/A | |
Recruiting |
NCT05380856 -
Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual Dysfunction
|
N/A |